Archive · 29 Sep 2026
AI-Powered Dialysis Ecosystem Secures UK MHRA Registration
Lord’s Mark Industries has developed an Indian dialysis system called Renalyx.
The system is designed to help provide dialysis treatment in hospitals and homes.
It uses a computer platform called RenalOS to monitor treatment and support healthcare workers.
The company says its system has been registered with the UK’s medical-device regulator, the MHRA.
Lord’s Mark plans to export the machines to the UK and other UK-allied countries from early January 2027.
It also wants to explore running its own dialysis centres.
The company describes Renalyx as an AI-powered care system rather than just a machine.
However, MHRA registration does not automatically mean that the system has been certified or approved by the UK authorities.
Further regulatory, clinical and market-access requirements may apply.
Lord’s Mark Industries says its Renalyx haemodialysis system has secured registration with the UK Medicines & Healthcare products Regulatory Agency.
The registration lists Renalyx Health Systems Pvt. Ltd. as manufacturer for institutional and home-use haemodialysis systems under GMDN Code 58131.
Lord’s Mark says it plans to begin exporting the machines to the UK and UK-allied countries in early January 2027.
Renalyx combines a dialysis machine with RenalOS, AI-powered clinical intelligence, remote monitoring and operational management.
The MHRA states that registration does not itself constitute accreditation, certification or approval by the UK Competent Authority.
- Who
- Lord’s Mark Industries Limited, through Renalyx Health Systems Pvt. Ltd., and the UK Medicines & Healthcare products Regulatory Agency.
- What
- Registration of the Renalyx haemodialysis system for institutional and home use.
- When
- The company says exports are planned to begin in early January 2027; the registration date is not specified.
- Where
- The United Kingdom, with potential expansion to UK-allied international markets.
- Why
- To support international deployment of the technology and explore supplying dialysis systems and operating dialysis centres.
Company’s Position
Regulatory Context
Significance of the registration
Company’s Position
Lord’s Mark presents the registration as a major milestone for its Indian-built, AI-powered renal-care ecosystem and describes it as a gateway to the UK and UK-allied markets.
Regulatory Context
The MHRA communication confirms manufacturer and device registration but clarifies that registration is not itself accreditation, certification or approval by the UK Competent Authority.
International expansion
Company’s Position
Lord’s Mark plans to export Renalyx machines from early January 2027 and explore supplying healthcare providers as well as establishing and operating its own dialysis centres.
Regulatory Context
The company’s expansion remains subject to applicable regulatory, clinical and market-access requirements in the relevant markets.
Technology claims
Company’s Position
The company describes Renalyx and RenalOS as an integrated AI-powered ecosystem offering treatment monitoring, predictive alerts, decision support and continuity of care beyond dialysis sessions.
Regulatory Context
The articles report these capabilities as company descriptions and do not provide independent validation of the system’s claimed clinical performance.
- Company
- Lord’s Mark Industries Limited
- Manufacturer
- Renalyx Health Systems Pvt. Ltd.
- Device
- Renalyx haemodialysis system
- Regulator
- Medicines & Healthcare products Regulatory Agency, United Kingdom
- Intended use
- Institutional and home haemodialysis
- GMDN code
- 58131
- Planned exports
- Early January 2027
- Regulatory limitation
- Registration does not itself constitute accreditation, certification or approval by the UK Competent Authority.
